{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:45:46Z","timestamp":1787021146989,"version":"build-2736575974"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>To examine real-world treatment patterns and effectiveness among patients with metastatic triple-negative breast cancer (mTNBC) in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN<\/jats:title>\n                    <jats:p>Retrospective, observational study using Flatiron Enhanced Datamart electronic health records from patients diagnosed with mTNBC between January 1, 2018, and June 30, 2023, who received \u22651 line of therapy (LoT) for metastatic disease. Patients were followed until date of death, last recorded activity, or data cutoff (December 30, 2023). Patient characteristics, treatments received from LoT1-5, and clinical outcomes (overall and by LoT) were described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The cohort comprised 1,044 patients. Most were female (99.2%); the median age was 61 years (IQR, 52-71); 52.1% were White and 21.7% were Black. The most common drug class in all LoTs was chemotherapy, as monotherapy or in combination with other agents: LoT1 85.5%, LoT2 73.2%, LoT3 65.8%, LoT4 64.7%, and LoT5 71.7%. Among patients with known PD-L1 status (n = 367), 109 (29.7%) were PD-L1\u2013positive and 258 (70.3%) were PD-L1\u2013negative. For the overall cohort, the median real-world overall survival (rwOS) from diagnosis was 14.0 (95% CI, 12.9 to 16.0) months. Real-world progression-free survival was 4.5 (95% CI, 4.0 to 5.0) months in LoT1 and 4.1 (95% CI, 3.5 to 4.9) months in LoT2. The median rwOS was 18.6 (95% CI, 15.2 to 24.4) months in the PD-L1\u2013positive cohort versus 12.7 (95% CI, 11.0 to 16.0) months in the PD-L1\u2013negative cohort. From December 1, 2021, onward, immunotherapy was received in LoT1 by 63.6% (21\/33) of patients who had PD-L1\u2013positive tumors and by 84.6% (33\/39) of patients with PD-L1\u2013positive tumors across all LoTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Real-world clinical outcomes in patients with mTNBC in the United States remain poor, particularly for patients with PD-L1\u2013negative disease. There is an unmet need for more effective treatments for mTNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00822","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T20:59:32Z","timestamp":1767819572000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Treatment Patterns and Outcomes for Patients With Metastatic Triple-Negative Breast Cancer in the United States: An Observational Study"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1239-1681","authenticated-orcid":true,"given":"Simon M.","family":"Collin","sequence":"first","affiliation":[{"name":"AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0267-4837","authenticated-orcid":true,"given":"Sam","family":"Hillman","sequence":"additional","affiliation":[{"name":"AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0225-507X","authenticated-orcid":true,"given":"Chintal H.","family":"Shah","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Tank","sequence":"additional","affiliation":[{"name":"AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4020-5871","authenticated-orcid":true,"given":"Manali","family":"Bhave","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3597-0050","authenticated-orcid":true,"given":"Tiffany A.","family":"Traina","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"e_1_3_8_2_2","unstructured":"GLOBOCAN: https:\/\/gco.iarc.fr\/today\/en"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i3.164"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9083055"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0067"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08320-7"},{"key":"e_1_3_8_9_2","first-page":"265","article-title":"Diagnosis, prognosis, and treatment of triple-negative breast cancer: A review","volume":"17","author":"Jie H","year":"2025","unstructured":"Jie H, Ma W, Huang C: Diagnosis, prognosis, and treatment of triple-negative breast cancer: A review. Breast Cancer (Dove Med Press) 17:265-274, 2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"e_1_3_8_11_2","unstructured":"National Cancer Institute (NCI) Surveillance Epidemiology and End Results Program: Cancer stat facts: Female breast Cancer subtypes. 2021. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102672"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad240"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.731535"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.801"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S206949"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"e_1_3_8_23_2","unstructured":"European Society for Medical Oncology (ESMO): ESMO metastatic breast cancer living guidelines. https:\/\/www.esmo.org\/living-guidelines\/esmo-metastatic-breast-cancer-living-guidelines\/triple-negative-breast-cancer"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0127"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.05.023"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0228"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.001"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01409"},{"key":"e_1_3_8_29_2","unstructured":"US Food and Drug Administration (FDA): TRODELVY\u00ae (sacituzumab govitecan-hziy) for injection for intravenous use. Initial US approval 2020. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761115s058lbl.pdf"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_8_31_2","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V.4.2025. \u00a9 National Comprehensive Cancer Network Inc. 2025. All rights reserved. Accessed [July 16 2025]. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00439-5"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1021"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06407-0"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0606-0"},{"key":"e_1_3_8_36_2","first-page":"100119","article-title":"An update on breast cancer chemotherapy-associated toxicity and their management approaches","volume":"9","author":"Langeh U","year":"2023","unstructured":"Langeh U, Kumar V, Ahuja P, et al: An update on breast cancer chemotherapy-associated toxicity and their management approaches. Health Sci Rev 9:100119, 2023","journal-title":"Health Sci Rev"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T20:59:33Z","timestamp":1767819573000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":35,"alternative-id":["10.1200\/OP-25-00822"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00822","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2025-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-25-00822"}}